-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Masupirdine in Dementia Associated With Alzheimer’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masupirdine in Dementia Associated With Alzheimer's Disease Drug Details: Masupirdine (SUVN-502) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Influenza [Strain A/H5N1] Vaccine in Pandemic Influenza
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Influenza [Strain A/H5N1] Vaccine in Pandemic InfluenzaDrug Details:Vaccine candidate was under development for the prophylaxis of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Cyproheptadine Hydrochloride + Prazosin Hydrochloride) in Alcohol Addiction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Cyproheptadine Hydrochloride + Prazosin Hydrochloride) in Alcohol Addiction Drug Details: KT-110 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Lymphoma Drug Details: Cellular therapy is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Solid Tumor Drug Details: Cellular therapy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Relapsed Multiple Myeloma Drug Details: Cellular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Relapsed Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Refractory Multiple Myeloma Drug Details: Cellular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Refractory Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-1070806 in Crohn’s Disease (Regional Enteritis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GSK-1070806 in Crohn's Disease (Regional Enteritis) Drug Details: GSK-1070806 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.